Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q2 FY24 Earnings Presentation
26 slides from Rossari Biotech's earnings presentation, Oct 22, 2023
Slide 1: Exchange filing cover letter: Q2 FY24 Earnings Presentation
October 22, 2023 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Ltd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Plot No.C/1, Rotunda Building, Phiroze Jeejeebhoy Towers ‘G’Block, Bandra- Kurla Complex Dalal Street, Fort-Mumbai 400 023 Bandra East-Mumbai 400 051 Fa
Slide 2: Rossari Biotech Limited Q2 & H1 FY24 Results Presentation
Rossari Biotech Limited Q2 & H1 FY24 Results Presentation October 21, 2023
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to b
Slide 4: Q2 FY24 Results Overview
Q2 FY24 Results Overview 3
Slide 5: Q2 FY24 – Key Financial Highlights
Q2 FY24 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. In cr) (Rs. In cr) (Rs. In cr) Record Quarterly Highest quarterly Revenue Highest quarterly EBITDA Highest quarterly PAT Performance 63.6 32.9 483.5 57.7 56.5 29.2 410.6 425.4 23.9 Q2 FY24 Q1 FY24 Q2 FY23 Q2 FY24 Q1 FY24 Q2 F
Slide 6: Management Message
Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said "We are pleased to report a record quarter for Rossari, with the best ever performance both in terms of Revenue and Profi
Slide 7: Key Developments
Key Developments The Company announces Capacity Expansion Plans Expansion at Dahej Facility of Rossari Biotech Limited: o The facility is slated for an expansion to introduce a 20,000 MTPA capacity dedicated to products related to HPPC in the specialty chemical space and producing ingredients for
Slide 8: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated Particulars (Rs. crore) Q2 FY24 Q2 FY23 Y-o-Y Shift (%) H1 FY24 H1 FY23 Y-o-Y Shift (%) Revenues from Operations 483.5 425.4 14% 894.1 860.1 4% Total Expenditure • COGS 342.8 301.8 14% 632.3 612.6 3% • Employee benefits expense 27.5 24.1 14% 52.0 47.6 9% • Other
Slide 9: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY AND LIABILITIES CONSOLIDATED CONSOLIDATED ASSETS CONSOLIDATED CONSOLIDATED As on 30th Sept As on 30th Sept As on 31st March As on 31st March Particulars (Rs. crore) 2023 (un- Particulars (Rs. crore) 2023 (un- 2023 (Audited) 2023 (Audited) Audited) Audited) EQUITY AS
Slide 10: Consolidated Cash Flows
Consolidated Cash Flows As on 30th Sept As on 30th Sept As on 30th Sept As on 30th Sept Particulars (Rs. crore) Particulars (Rs. crore) 2023 (Unaudited) 2022 (Unaudited) 2023 (Unaudited) 2022 (Unaudited) Cash flows from operating activities Cash flows from investing activities Profit before tax 84.2
Slide 11: Q2 FY24 - Segment-wise Details
Q2 FY24 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) Q2 FY24 Q1 FY24 Q2 FY23 367.1 301.2 303.9 95.9 80.9 91.3 20.5 28.5 30.2 HPPC TSC AHN Shift (Y-o-Y) % 20.8% 5.0% -32.1% Shift (Q-o-Q) % 21.9% 18.5% -28.1% Note: 1) All figures, unless mentioned otherwise, are on a consolidated b
Slide 12: Q2 FY24 - Financial and Operational Discussions
Q2 FY24 - Financial and Operational Discussions Net Revenue Q2 FY24 Revenues from operations stood at Rs. 483.5 crore, up 14% Y-o-Y The Company delivered healthy topline performance during the quarter, despite ongoing challenging external environment o HPPC division delivered robust performance fo
Slide 13: Financial Performance Snapshot
Financial Performance Snapshot Revenue (Rs. crore) EBITDA (Rs. crore) PAT (Rs. crore) 223 107 1,483 1,656 183 98 80 894 124 121 62 709 FY21 FY22 FY23 H1 FY24 FY21 FY22 FY23 H1 FY24 FY21 FY22 FY23 H1 FY24 • Consistent growth trajectory over the past three years, driven by both organic and inorganic g
Slide 14: Company Overview
Company Overview 13
Slide 15: Rossari – At a Glance
Rossari – At a Glance Technocrat promoters with 45+ 8* 354,100* 4* 34% 24% cumulative years of Manufacturing MTPA Revenue CAGR % PAT CAGR % experience in the R&D Facilities facilities Capacity Installed (FY19-23) (FY19-23) specialty chemicals industry Rossari – A Specialty-Chemical manufacturer prov
Slide 16: Business Overview
Business Overview One of the leading specialty chemicals manufacturer delivering differentiated & tailor-made solutions across Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health and Nutrition (AHN) businesses HPPC TSC AHN One of the fastest-gr
Slide 17: Strengthening Market Presence
Strengthening Market Presence Growing client base Diversifying of over 1,000 customer base to customers both lower India and concentration risk International Widening Increasingly tapping distribution new segments across network to drive domestic and reach international markets Company’s focus towar
Slide 18: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities Located on 8.6 acres of land Manufacturing Fungible manufacturing capabilities for powders, granules and liquids Facility at Facility has a comprehensive range of testing & packaging capabilities Silvassa Effluent treatment facility, with 2,500 MT bulk stora
Slide 19: Strategic Growth Levers
Strategic Growth Levers Augmenting product portfolio with enhanced emphasis on green solutions Increase wallet share across existing customer base while also tapping new customer segments Identifying and developing new niches in product offerings by leveraging R&D capabilities Capitalize on cros
Slide 20: Inorganic Initiatives
Inorganic Initiatives Executed two synergistic acquisitions and one strategic investment in FY 2022 complementing the ethos of Rossari’s business model SF Unitop Chemicals Tristar Intermediates Romakk Chemicals Prominent player in the field of Preservatives, Primarily engaged in the business of manu
Slide 21: Key Synergies from Acquisitions
Key Synergies from Acquisitions Strategic & value-accretive acquisitions accelerate growth and drive economies of scale Augmented Pooling together Expansion of of related Inorganic presence in Extension of addressable technologies investments Specialty manufacturing domestic and within operational C
Slide 22: Focus on Green & Sustainable Chemical Solutions
Focus on Green & Sustainable Chemical Solutions Specialists in producing environmentally- benign substitutes that replace legacy and harmful products Focus on green, sustainable and cost neutral products Minimizing carbon footprint of manufacturing processes while maximizing customer benefits Aggres
Slide 23: Annexure
ROSSARI making you more eompettive Annexure 22
Slide 24: Conference Call Details
Conference Call Details Q2 FY2024 Earnings Conference Call Time 05:00 p.m. IST on Monday, November 23, 2023 To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link: Pre-registration Primary dial-in number + 91 22 62
Slide 25: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a For further information, please contact: Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Ketan Sablok Headquartered at Mumbai, India, the Company operates Ro
Slide 26: Thank you
Thank y#u making you more eompettive